BMP signaling inhibition overcomes chemoresistance of prostate cancer.
BMP signaling
Chemoresistance
DMH1
cancer stem cells
prostate cancer
xenograft
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
03
2023
accepted:
17
08
2023
medline:
11
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
Chemoresistance is a major therapeutic challenge to prostate cancer and its underlying molecular mechanism is poorly understood. Previously, it has been suggested that bone morphogenetic protein (BMP) signaling is down-regulated during the prostate cancer progression from the early androgen-sensitive stage to the metastatic castration-resistant stage. However, no literature reports are available for BMP signaling in more advanced-chemoresistant prostate cancer. In this study, we found the expression levels of the BMP type I receptor members, Activin-like kinase-2 (ALK2) and Activin-like kinase-3 (ALK3), were significantly higher in the chemoresistant prostate cancer cells than those in the chemosensitive prostate cancer cells. In addition, the phospho-Smad1/5/9 proteins, the pivotal intracellular effectors of the BMP signaling, were notably elevated in the chemoresistant prostate cancer cells over the chemosensitive prostate cancer cells, indicating that BMP signaling is highly activated in the chemoresistant prostate cancer cells. We also found that BMP signaling inhibition with either DMH1 or the knockdown of ALK2/ALK3 sensitized chemoresistant prostate cancer cells to the chemotherapy drug docetaxel in a dose-dependent manner. Our further study indicates that DMH1 suppressed the migration and invasion of chemoresistant prostate cancer cells
Types de publication
Journal Article
Langues
eng
Pagination
4073-4086Informations de copyright
AJCR Copyright © 2023.
Déclaration de conflit d'intérêts
None.
Références
Oncogene. 2014 Sep 4;33(36):4451-63
pubmed: 24096485
Cancer Treat Rev. 2017 Jun;57:16-27
pubmed: 28527407
Asian J Urol. 2016 Oct;3(4):203-210
pubmed: 29264188
Mol Ther Oncolytics. 2017 Oct 24;8:1-13
pubmed: 29234727
Oncol Rep. 2011 Aug;26(2):455-61
pubmed: 21567100
Asian Pac J Cancer Prev. 2013;14(9):4983-8
pubmed: 24175763
Cell Death Dis. 2012 Jan 26;3:e260
pubmed: 22278287
Oncotarget. 2016 Feb 9;7(6):6916-32
pubmed: 26755648
Cancer Res. 1997 Oct 1;57(19):4427-31
pubmed: 9331107
PLoS One. 2011;6(7):e21366
pubmed: 21754986
Cancer Res. 2000 Jun 1;60(11):2840-4
pubmed: 10850425
Nat Rev Urol. 2013 Sep;10(9):522-8
pubmed: 23797341
Lab Anim. 2020 Feb;54(1):99-110
pubmed: 31665969
Nat Rev Clin Oncol. 2011 Jan;8(1):12-23
pubmed: 20859283
PLoS One. 2012;7(6):e40021
pubmed: 22768203
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Am J Transl Res. 2020 Sep 15;12(9):5797-5807
pubmed: 33042459
Oncotarget. 2014 Dec 15;5(23):11939-56
pubmed: 25460502
J Cell Biol. 2012 Aug 6;198(3):281-93
pubmed: 22869594
Mol Cancer Res. 2017 Feb;15(2):128-140
pubmed: 27856956
J Exp Clin Cancer Res. 2018 Jul 16;37(1):156
pubmed: 30012194
J Cell Biochem. 2011 Aug;112(8):2125-37
pubmed: 21465536
Cancer Cell. 2012 Sep 11;22(3):373-88
pubmed: 22975379
J Mol Cell Biol. 2010 Dec;2(6):318-32
pubmed: 21098050
Prostate. 2014 Nov;74(15):1498-505
pubmed: 25175483
Cancer Chemother Pharmacol. 2005 Mar;55(3):277-85
pubmed: 15565326
Cancer Res. 2017 Aug 1;77(15):4026-4038
pubmed: 28611046
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Histol Histopathol. 2007 Oct;22(10):1129-47
pubmed: 17616940
Prostate. 2004 May 15;59(3):234-42
pubmed: 15042598
J Cell Commun Signal. 2022 Jun;16(2):191-205
pubmed: 34608584
Cancer Sci. 2013 Mar;104(3):398-408
pubmed: 23281849
J Cell Biochem. 2015 Jul;116(7):1341-9
pubmed: 25640606
Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165432
pubmed: 30904611
J Cell Biochem. 2013 Jun;114(6):1286-93
pubmed: 23192682
Prostate. 2007 Jun 15;67(9):955-67
pubmed: 17440963
Cancer Res. 2013 Jan 15;73(2):1020-30
pubmed: 23243027
J Pharmacol Exp Ther. 2005 Jul;314(1):355-62
pubmed: 15831436
Gene. 2022 Jun 15;827:146448
pubmed: 35337852
PLoS One. 2014 Mar 06;9(6):e90748
pubmed: 24603907
Asian Pac J Cancer Prev. 2013;14(10):6135-40
pubmed: 24289639
Oncogene. 2004 Oct 7;23(46):7651-9
pubmed: 15354178
Curr Cancer Drug Targets. 2014;14(3):225-40
pubmed: 24720286
Gastric Cancer. 2012 Oct;15(4):440-50
pubmed: 22395309
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
J Int Med Res. 2010 Jul-Aug;38(4):1428-35
pubmed: 20926015
Cytokine Growth Factor Rev. 2005 Jun;16(3):251-63
pubmed: 15871923
Anticancer Res. 2000 Jul-Aug;20(4):2449-56
pubmed: 10953309
Sci Rep. 2018 Aug 6;8(1):11739
pubmed: 30082842
Oncogene. 2015 May 7;34(19):2437-49
pubmed: 24998846
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11737-42
pubmed: 11562465
Prostate. 1994 Apr;24(4):204-11
pubmed: 8146069
JAMA. 1963 Nov 2;186:481-3
pubmed: 14053350
Front Oncol. 2018 Aug 28;8:347
pubmed: 30211124